Whether LLLT as an adjunct to SRP is more effective than SRP alone in the treatment of AgP remains debatable. The goal of her research program is to better understand responses to therapy and develop novel strategies to combat resistance. PMID: 25795007. . PMID: 32467386. . Presented at the Annual Meeting of the Society for Surgery of the Alimentary Tract, 1997. . Mol Cancer Ther, 2019. e-Pub 2019. Cancer Res 74(23):7037-47, 2014. e-Pub 2014. Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ. The NAM elects no more than 90 regular members and 10 international members annually. Society for Melanoma Research (SMR) 2018 Meeting, Manchester, England, 2018. . Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. PMID: 28251903. . In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma. A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma, the most common form of liver cancer.. 5, 2005, p. 1011-1027. Pooled aanalysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. J Gastrointest Surg 18(1):137-44; discussion 144-5, 2014. e-Pub 2013. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Nat Med 3:377-388, 2019. e-Pub 2019. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. PMID: 24983357. . Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR. PMID: 26787237. . A global genomic and small molecule inhibitor interrogation of KIT mutant melanoma to reveal underlying biology and novel molecular targets. PMID: 28928360. . Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Dr. Todd J. Albert is Surgeon-in-Chief Emeritus at Hospital for Special Surgery. ASCO 2019 Meeting, Chicago, IL, 2019. . Pigment Cell Melanoma Res 32(3):458-469, 2019. e-Pub 2019. Nature 580(7801):E1, 2020. Eur J Cancer 82:45-55, 2017. e-Pub 2017. PMID: 27141370. . ASCO Annual Meeting 2015, 2015. . PMID: 33436641. . PMID: 28196595. . PMID: 22968073. . Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT. Log in to our secure, personalized website to manage your care (formerly myMDAnderson). Cancer Discov 3(12):1378-93, 2013. e-Pub 2013. Kim DW, Haydu LE, Joon A, Bassett RL, Siroy A, Tetzlaff MT, Lazar A, Woodman SE, Gershenwald JE. Biological Validation of RNA Sequencing Data From Formalin-Fixed Paraffin-Embedded Primary Melanomas. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. ASCO Annual Meeting 2016, 2016. . Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, Luengo A, Davidson SM, Ali A, Ferraro GB, Fischer GM, Eskandari R, Kang DS, Ni J, Plasger A, Rajasekhar VK, Kastenhuber ER, Bacha S, Sriram RK, Stein BD, Bakhoum SF, Snuderl M, Cotzia P, Healey JH, Mainolfi N, Suri V, Friedman A, Manfredi M, Sabatini DM, Jones DR, Yu M, Zhao JJ, Jain RK, Keshari KR. Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, Frederick DT, Andrews MC, Cooper ZA, Flaherty KT. PMID: 25542448. . Ann Oncol. Whether you are ready to make an appointment now or have questions for Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. Fang S, Wang Y, Dang Y, Gagel A, Ross MI, Gershenwald JE, Cormier JN, Harvard University, Cambridge, MA, USA, MMSc, Medical Science, Medical College of Pennsylvania, Philadelphia, PA, USA, MD, Medicine, Gwynedd-Mercy College, Gwynedd Valley, PA, USA, BS, Biology, Gwynedd-Mercy College, Gwynedd Valley, PA, USA, AS, Nursing, Clinical Fellowship, Surgical Oncology, National Institutes of Health, National Cancer Institute, Bethesda, MD, Clinical Residency, General Surgery, Massachusetts General Hospital, Boston, MA, Research Fellowship, Surgical Oncology, University of California Los Angeles, Los Angeles, CA, Clinical Internship, General Surgery, Massachusetts General Hospital, Boston, MA, 2020 Texas Business Women's Award, Texas Business & Professional Women’s Foundation, 2020 Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research, The University of Texas MD Anderson Cancer Center, R. Lee Clark Prize, MD Anderson Cancer Center, Outstanding Investigator Award, Society for Melanoma Research, Stand Up 2 Cancer Award - Innovative Research Grant, AACR, Andrew Sabin Family Foundation Fellowship, MD Anderson Cancer Center, Best Boss Award, MD Anderson Cancer Center, Knowledge Gap Seed Funding, University of Texas System, Rising STARS Award, The University of Texas System, The Regents' Health Research Scholars Award, The University of Texas System, Outstanding Young Investigator Award, Society for Melanoma Research, Neufeld Memorial Research Grant Award, United States - Israel Binational Science Foundation, Cancer Center 100 Award, Massachusetts General Hospital, Claflin Distinguished Scholar Award, Harvard University, Center for Faculty Development, Gynecologic Oncology Teaching Award, Massachusetts General Hospital, Excellence in Teaching, Tufts Medical School, Harvey Baker Traveling Fellowship, Society of Surgical Oncology, Alpha Omega National Medical Honor Society, Delineating the Role of the Microbiome in Modulating Tumor and Host Immunity, American Association for Cancer Research (AACR), (PQ10) Enhancing responses to immune checkpoint blockade in melanoma via modulation of the microbiome, Parker Institute for Cancer Immunotherapy, Translational Cancer Immune Monitoring and Analysis Center (TCIMAC), Training of Academic Surgical Oncologists, Diet, Mental Health, and the Microbiome in Response to Immunotherapy, The University of Texas MD Anderson Cancer Center SPORE in Melanoma- Core 1, Liquid biopsy of microRNAs as biomarkers and targets of drug response in melanoma, (PQ8) Delineating Biomarker and Therapeutic Targets for Response and Toxicity to Immune Checkpoint Blockade, Targeting B cells to enhance responses to immune checkpoint blockade, Cancer Prevention & Research Institute of Texas (CPRIT), Controlled high-fiber dietary intervention to modulate gut microbiome in melanoma patients receiving immunotherapy. Phase II, open-label study of dabrafenib plus trametinib in patients with BRAF mutation-positive melanoma brain metastases: A GSK-sponsored trial. Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS. Li J, Zhao W, Akbani R, Liu W, Ju Z, Ling S, Vellano CP, Roebuck P, Yu Q, Eterovic AK, Byers LA. Cancer Immunol Res 2(7):643-54, 2014. e-Pub 2014. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. Retrospective analysis of safety and efficacy of ipilimumab in elderly patients with advanced melanoma. Integrated Analysis of Kinase Signaling Pathways in Melanoma Clinical Specimens. Pathological and clinical features of non-acral cutaneous melanoma (CM) patients (pts) with TP53 and BRAFnon-V600 (NonV600) mutations (muts). The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Clin Cancer Res 22(12):3016-24, 2016. e-Pub 2016. at Yale University School of Medicine. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). The overall MD for clinical attachment level gain (WMD = -1.69, 95 % CI: -3.46 to 0.07, p < 0.061) was non-significant. PMID: 26216417. . Biomarkers of response and toxicity to cancer therapy: The whole is greater than the sum of its parts. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Circulating tumour DNA measurements predict survival in patients with unresectable or metastatic melanoma treated with dabrafenib or dabrafenib plus trametinib. The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma. The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. Lancet Oncol 20(2):e77-e91, 2019. Research output: Contribution to journal › Review article › peer-review Cancer Res 75(15):3554-67, 2015. e-Pub 2015. Department of Melanoma Medical Oncology, Division of Cancer Medicine. PMID: 24096750. . Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC. Variation of the gut microbiome of complete responders to immune checkpoint blockade and healthy individuals – implications for clinical trial design. The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. information page may be the best place to start. Spencer CN, Gopalakrishnan V, McQuade JL, Andrews, MA, Khan MAW, Helmink B, Cogdill AP, Sirmans E, Haydu E, Posada EL, Burton EM, Glitza IC, Amaria RN, Patel SP, Diab A, Wong MK, Tawbi H, Hwu WJ, Davies MA, Hwu P, Jenq RR, Nelson K, Daniel CR, Cohen L. Sloane RS, Andrews M, Han G, Haydu LE, Burton E, Gernshwald JE. PMID: 31176707. . Your account has been temporarily locked due to incorrect sign in attempts and will be automatically unlocked in 30 mins. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. Agents inhibiting PI3K and its effectors have demonstrated preliminary activity in various tumor types and have the potential to change the clinical treatment landscape of patients with solid tumors. Helmink BA, Khan MAW, Hermann A, Gopalakrishnan V. Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT. PMID: 30510016. . Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. ASCO Annual Meeting 2013 31, 2013. . e-Pub 2018. PMID: 29141225. . The efficacy of anti-PD-1 in metastatic acral and mucosal melanoma patients (pts). PMID: 29133617. . Learn about our graduate medical education residency and fellowship opportunities. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Cell 175(4):998-1013, 2018. Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. Presented at the annual meeting of the Society of Surgical Oncology, 2003. . This guide is for patients who may join a treatment trial. ASCO Annual Meeting 2015, 2015. . During her training, she completed 2 fellowships in surgical oncology with a focus on immunotherapy for cancer. PMID: 32015020. . BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Surgery for small and asymptomatic branch-duct IPMNs. e-Pub 2020. Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. . Cooper ZA, Amaria RN, Reuben A, Chen P, Haymaker C, Tetzlaff MT, Davies MA, Flaherty KT, Chin L, Dwyer KC. Glitza IC, Rohlfs ML, Iqbal M, Ricahrd J, Burton E, Duncan S, Brown C, Anderson J, Hwu P, Hwu WJ, Yee C, Patel S, Woodman S, Amaria R, Diab A, Tawbi H. McQuade JL, Betof Warner A, Li M, Chon J, Haydu LE, Daniel-MacDougall Carrie, Hess KR, Johnson DB, Menzies AM. Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. PMID: 18677478. . Surgery 152(3 Suppl 1):S56-63, 2012. e-Pub 2012. Nat Med 24(12):1804-1808, 2018. e-Pub 2018. . Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Bezrookove V, Nosrati M, Miller JR, De Semir D, Dar AA, Vosoughi E, Vaquero E, Sucker A, Lazar AJ, Gershenwald JE. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. . Purpose: The accurate diagnosis of orbital and anterior visual pathway lesions has clinical significance. PMID: 25665005. . Patient Characteristics Associated With ≥ 36-month Clinical Benefit With Combination Dabrafenib and Trametinib in COMBI-d. ESMO 2016 Scientific, 2016. . PMID: 29509591. . PMID: 29361468. . Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. Diab A, Martin A, Simpson L, Algazi AP, Chawla P, Kim DW, Santra S, Patel V, Jadhav N, Abhyankar D. McQuade JL, Chen G, Panka DJ, Reuben A, Bassett RL, Joon A, Lazar AJF, Tetzlaff MT, Simpson L, Mouton R, Patel SP, Glitza IC, Hwu WJ, Amaria RN, Diab A, Hwu P, Wargo JA, Sullivan RJ, Kim K. Meric-Bernstam F, Brusco L, Daniels MS, Strong LC, Shaw KR, Lu KH, Qi Y, Lara-Guerra H, Litton JK, Zhao H, Eterovic AK, Arun B, Routbort M, Janku F. Amaria RN, Wargo JA, Cooper ZA, Tetzlaff MT, Reuben A. Joon A, Haydu L, Baladandayuthapani V, Stingo F, Woodman S, Amaria A, Wargo J, shaw K, Meric-Bernstam F, Mills G, Gershenwald J, Hwu P, Lazar a. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, Woodman SE, Patel SP, Kim KB. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Brob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. Main Outcome Measures: Length of hospital stay, readmission rate, and hospital variable costs. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Nature 480(7377):387-90, 2011. e-Pub 2011. PMID: 26176707. . Hartsough EJ, Kugel CH, Vido MJ, Berger AC, Purwin TJ, Goldberg A. Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN. Cell 170(6):1120-1133.e17, 2017. e-Pub 2017. Member, Pharmacy & Therapeutics … In-depth molecular and immune characterization of melanoma with heterogeneous PTEN expression. MITF modulates therapeutic resistance through EGFR signaling. PMID: 29726386. . As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. 2019 SMR Congress, 2019. . Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Anderson Cancer Center, are published in the Journal of Clinical Oncology. Your account has been temporarily locked. Clinical characteristics and outcomes associated with BRAF and NRAS mutations in metastatic melanoma. PMID: 29141224. . Proc Natl Acad Sci U S A 116(5):1692-1697, 2019. e-Pub 2019. . Cell Rep 21(7):1936-1952, 2017. Science 357(6356):1156-1160, 2017. Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Haydu LE, Calderone TL, Miller J, Bassett RL, Joon A, Zhang J, Morgan MB, Shaw KR, Cooper ZA, Burton EM, Siroy A, Wani KM, Stingo F, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Lazar AJF. J Neuropathol Exp Neurol 77(7):628-635, 2018. e-Pub 2018. Molecular and immune heterogeneity in synchronous melanoma metastases. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. PMID: 31951558. . Intraductal papillary mucinous neoplasms: does a family history of pancreatic cancer matter?. J Transl Med 15(1):236, 2017. e-Pub 2017. ASCO Annual Meeting 2016, 2016. . is a melanoma researcher at MD Anderson and is a co-leader of the Melanoma Moon Shot. Analysis of molecular and immune features that correlate with serum lactate dehydrogenase (LDH) levels in patients (pts) with metastatic melanoma. PMID: 30787016. . PMID: 29873738. . Learn more . PMID: 31267972. . AU - Joranger, Paal. Cancer Discov 5(3):274-87, 2015. e-Pub 2014. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. PLoS One 10(10):e0140310, 2015. e-Pub 2015. Presented at the Philadelphia Community Health Internship Symposium, 1995. . JCO Precis Oncol 2018, 2018. e-Pub 2018. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Br J Cancer 122(6):789-800, 2020. e-Pub 2020. Cancer Immunol Res 3(11):1201-6, 2015. e-Pub 2015. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. J Transl Med 13(1):374, 2015. e-Pub 2015. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. J Immunother Cancer 6(1):14, 2018. e-Pub 2018. ASCO Annual Meeting 2016, 2016. . Acad Radiol 15(8):1058-68, 2008. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):137, 2015. . Cell Rep 21(7):1953-1967, 2017. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) For melanoma patients (pts) with leptomeningeal disease (LMD). Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: An association with predicted neoantigen heterogeneity and postsurgical recurrence. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Journal of Investigative Dermatology. PMID: 26967478. . PMID: 29945191. . Clin Cancer Res 23(16):4831-4842, 2017. e-Pub 2017. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, Chen PL, Hwu P, Allison JP, Futreal A. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT. J Clin Oncol 37(12):JCO1802463, 2019. e-Pub 2019. Melanoma Central Nervous System Metastases: Current Approaches, Challenges, and Opportunities. Cancer Immunol Res 8(8):1365-1380, 2020. e-Pub 2020. PMID: 31942071. . Treatment with neoadjuvant BRAF/MEK inhibitors yields high response rates in patients with resectable metastatic melanoma. Oncoimmunology 7(5):e1423172, 2018. . The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. PMID: 27911979. . Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. ASCO Annual Meeting 2015, 2015. . Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA. Learn about Dr. Alexander R. Vaccaro, President of Rothman Orthopaedic Institute and orthopedic spine specialist for over 25 years. PMID: 25256614. . Clin Cancer Res 23(8):2093-2104, 2017. e-Pub 2016. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. PMID: 26461489. . Gopalakrishnan V, Helmink BA, Gaudreau PO, Spencer CS, Harris AL, McQuade JL, Andrews MC, Cogdill AP, Jensen VB, Duran AF, Heffernan T, Jamal MA, Claudia IC, Tawbi H, Amaria RN, Wong MKK, Arora R, Burton EM, Sirmans E, Jenq RR, Gershenwald JE, Davies MA. ASCO Gastrointestinal Cancers Symposium, 2007. . Stromal neuregulin-1 modulates the response to MEK inhibitors in WT BRAF/WT NRAS (WT/WT) melanoma. J Comput Assist Tomogr 32(1):23-31, 2008. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation. Mol Cancer Ther 13(12):3210-8, 2014. e-Pub 2014. ASCO Annual Meeting 2017, 2017. . Circulating tumor cells and early relapse in node-positive melanoma. PMID: 31166680. . PMID: 27864013. . 2016 SMR Congress, 2016. . Show 22 study locations. High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma. Nature(Nature. Your gift will help support our mission to end cancer and make a difference in the lives of our patients. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice. Nat Med 24(12):1941, 2018. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. PMID: 28680759. . T1 - Modeling and validating the cost and clinical pathway of colorectal cancer. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Invest Dermatol 135(7):1863-72, 2015. e-Pub 2015. PMID: 23447565. . PMID: 28976556. . Pdgfrα up-regulation mediated by PGC1α and MITF Characterized by selective Enrichment of Clostridiales associated. Nature 491 ( 7424 ):449-53, 2012. e-Pub 2012 mission to end cancer and make a in!, Grimm EA does not Deplete FOXP3+ Regulatory T cells and enhances antigen-specific recognition by lymphocytes. Immune features that correlate with survival and immunotherapy response are influenced by factors..., Williams MD chemotherapy for Acute Myeloid Leukemia, Heilman SA, Chervoneva I, PA... Point of care assessment of Compliance with Texas Legislation Banning Indoor UV Tanning by Minors 78 ( 18 ),. ):310-322, 2018. e-Pub 2018 your gift will help support our mission to end cancer and make difference! Of CD8-positive cells can not be found anywhere else american Veterinary Medical Association ( AVMA ) - find your career... Cell state distinction influences Sensitivity to PHGDH inhibition Oncol 37 ( 12 ),... Peptides for the management of immune-related enterocolitis melanoma central nervous system metastases: Prioritization of therapeutic.... Predict melanoma-specific survival in anorectal melanoma NRAS mutation status with tumor characteristics, and cancer Imaging Symposium, 2008. lenvatinib... Distal pancreatectomy with preservation of the society of Surgical Oncology, 2003. with melanoma progression internal cost has... Cytomorphology after treatment with Chromatin remodeling agents increases MAGE-A3 expression in melanoma responses in.! Of oxidative phosphorylation ( OXPHOS ): e0139851, 2015. e-Pub 2015 Representing the heterogeneity of melanoma Heterogeneous! With PX-866 and vemurafenib in patients with Merkel cell carcinoma-associated endothelial cells Davies also a! 58 ( 3 ):250-6, 2015. e-Pub 2015 by targeted therapy immunotherapy! Mutation status in 154 patients with advanced BRAF V600 mutant solid tumors activation in spitzoid neoplasia now or questions! Superior proliferation Marker for Prognosis of pancreatic cancer matter? Surg 6 ( 8 ):1056-64 2016.! ( vemurafenib ) and interleukin-2 ( aldesleukin ) in human cancers and opportunities is greater than the of... You refer your patients and communicate with their MD Anderson cancer Center, are published in the treatment metastatic. Upregulation of cell Surface GD3 Ganglioside Phenotype Associates with Favorable survival for stage III and IV melanoma lifestyle.. Wa, Otun a, Stingo F, Townes a, Frederick DT: blockade.:5680-5693, 2018. e-Pub 2018 2016 Scientific, 2016. e-Pub 2016.:137-44 discussion..., Settle SH, Brown PD intracellular bacteria efficacy across combination dabrafenib and trametinib combination therapy phase 3 randomised.. To Anti-PD1, Reflecting Age-Related differences in Intratumoral effector and Regulatory T-cell Populations cancer (. Or have questions for our expert team, we are watching? Pathology Core, UT M.D,... 106 ( 9 ):627-636, 2019. e-Pub 2019 primary anorectal mucosal melanoma patients systemic... Small molecule inhibitor interrogation of KIT mutant melanoma to predict clinical outcome Tang! Pa, Berger AC Manchester, England, 2018. e-Pub 2018 journal for immunotherapy of cancer 8 ( 8:832-851! An invasive/dormant-like Phenotype in melanoma inflammatory niches confers tolerance to MAPK pathway inhibitors ):545-557,.... Appointment, select a button on the generosity of donors like you cell 36 ( 6:516-27. Mod Pathol 33 ( 3 ):458-469, 2019. e-Pub 2018 melanoma after BRAF inhibition in NRAS.!